Puma Biotechnology Q3 2026 Results: Net Income $5.96M, Down 32.7% YoY
Puma Biotechnology reported total revenue of $55.1 million for the third quarter of 2026, driven primarily by NERLYNX product sales. While the company remained profitable with a net income of $6.0 million, this was a decrease from $8.8 million in the prior year's third quarter due to higher research and development expenses.
- Key figure
- Net income $5.96M · -32.7% YoY